Healthcare / BiotechnologyShanghai
$18.18
+0.41 (+2.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-161.7M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.9%
↓Gross Margin
45.4%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-28.1%
FCF CAGR
—
FCF margin
-48.5%
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $193.5M · net income $-107.4M · FCF $-93.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $193.5M | $193.5M | $125.9M | $171.3M | $521.6M |
| Net Income | $-107.4M | $-107.4M | $-157.2M | $-84.4M | $159.3M |
| EBITDA | $-71.0M | $-71.0M | $-124.2M | $-57.7M | $220.6M |
| EPS | -0.98 | -0.98 | -1.41 | -0.75 | 1.72 |
| Gross Margin | 45.4% | 45.4% | 55.9% | 64.6% | 69.9% |
| Operating Margin | -62.2% | -62.2% | -123.9% | -61.4% | 37.4% |
| Net Margin | -55.5% | -55.5% | -124.9% | -49.3% | 30.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Current Ratio | 13.76 | 13.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-93.8M | $-93.8M | $-161.7M | $-170.9M | $7.0M |
| Returns | |||||
| ROE | -7.9% | -7.9% | -10.7% | -5.1% | 8.9% |
| Valuation | |||||
| P/E | — | — | — | — | 18.14 |
| EV/EBITDA | — | — | — | — | 8.60 |
| P/B | 1.48 | 1.48 | 2.16 | 2.02 | 1.62 |
| Growth & Yield | |||||
| Revenue Growth | 53.7% | 53.7% | -26.5% | -67.2% | — |
| EPS Growth | 30.9% | 30.9% | -88.0% | -143.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.41 → -0.98
Residual
-1.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.